Neuburgh Advisers’s Kyntra Bio KYNB Stock Holding History

Neuburgh Advisers’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-41	Closed	-$56K	–	916
2019 Q1	$56K	Sell	41 -5	-11%	-$6.78K	﹤0.01%	844
2018 Q4	$53K	Buy	+46	New	+$51.7K	﹤0.01%	825

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Neuburgh Advisers's KYNB Position: Q2 2019 in Review

Neuburgh Advisers sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 41 shares — an estimated $56K sold.

Neuburgh Advisers first reported a position in KYNB in Q4 2018 and held it in 2 quarters. The position peaked at $56K in Q1 2019. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

Neuburgh Advisers reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
Neuburgh Advisers sold 41 Kyntra Bio shares in Q2 2019, an estimated $56K.
Neuburgh Advisers first reported a position in Kyntra Bio in Q4 2018 and held it in 2 quarters.
Neuburgh Advisers's Kyntra Bio position peaked at $56K in Q1 2019.
190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Neuburgh Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.